Trial Profile
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma
- Focus Adverse reactions; Therapeutic Use
- 14 Apr 2023 Planned End Date changed from 31 Dec 2027 to 31 Dec 2026.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
- 14 Jan 2023 Planned End Date changed from 31 Dec 2027 to 31 Dec 2026.